Corporate News     01-Feb-22
Alembic Pharmaceuticals receives USFDA approval for Clarithromycin Tablets
Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Clarithromycin Tablets USP, 250 mg and 500 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Biaxin Filmtab Tablets, 250 mg. and 500 mg, of AbbVie Inc. (AbbVie).

Clarithromycin Tablets are a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in acute bacterial exacerbation of chronic bronchitis in adults; acute maxillary sinusitis; community-acquired pneumonia; pharyngitis/tonsillitis; uncomplicated skin and skin structure infections; acute otitis media in paediatric patients; treatment and prophylaxis of disseminated Mycobacterial infections; Helicobacter pylori infection and duodenal ulcer disease in adults.

Clarithromycin Tablets USP, 250 mg and 500 mg have an estimated market size of US$ 11 million for twelve months ending September 2021 according to IQVIA.

Previous News
  Alembic Pharmaceuticals consolidated net profit rises 11.70% in the June 2024 quarter
 ( Results - Announcements 08-Aug-24   15:21 )
  Volumes spurt at Blue Star Ltd counter
 ( Hot Pursuit - 20-Sep-23   14:30 )
  Alembic Pharmaceuticals receives USFDA tentative approval for Ribociclib Tablets
 ( Corporate News - 01-Apr-24   11:51 )
  Alembic Pharmaceuticals gets Form 483 with 2 observations from USFDA
 ( Hot Pursuit - 01-Sep-22   11:34 )
  Alembic Pharmaceuticals to table results
 ( Corporate News - 24-Apr-23   17:42 )
  Alembic Pharmaceuticals resumes operations at Namthang unit
 ( Corporate News - 01-Feb-24   20:15 )
  Alembic Pharmaceuticals fixes record date for interim dividend
 ( Market Beat - Reports 27-Jul-22   14:22 )
  Alembic Pharmaceuticals receives NCLT approval for scheme of arrangement
 ( Corporate News - 01-Sep-22   12:36 )
  Alembic receives USFDA tentative approval for Fesoterodine Fumarate ER Tablets
 ( Corporate News - 02-Feb-22   10:54 )
  Alembic Pharmaceuticals' injectable facility undergoes USFDA inspection
 ( Corporate News - 01-Sep-22   11:50 )
  Alembic Pharmaceuticals consolidated net profit declines 39.70% in the December 2021 quarter
 ( Results - Announcements 10-Feb-22   15:37 )
Other Stories
  Just Dial announces board meeting date
  05-Oct-24   10:11
  L&T Finance schedules board meeting
  05-Oct-24   10:11
  Australian Premium Solar (India) announces board meeting date
  05-Oct-24   10:11
  Reliance Industrial InfraStructure declare Quarterly Result
  05-Oct-24   10:11
  PVV Infra to convene board meeting
  05-Oct-24   10:06
  Avenue Supermarts declare Quarterly Result
  05-Oct-24   10:06
  Fortis Healthcare to hold board meeting
  05-Oct-24   10:06
  Syngene International to convene board meeting
  05-Oct-24   10:06
  Srestha Finvest to conduct board meeting
  05-Oct-24   10:06
  Spright Agro schedules board meeting
  05-Oct-24   10:05
Back Top